United States

The European subsidiary of Matthews, a US provider of 'memorialisation products', such as caskets and memorial plaques, has launched a €50m Schuldschein, which could grow based on demand from lenders.

Asia is gearing up for a bumper week of IPOs, with two $2bn deals launching on Monday and other smaller-sized floats vying for investor attention in what has been an action-packed October.

US borrowers exploited a quieter week to pre-fund their 2017 maturities, enjoying strong demand and tight pricing as the prospect of an interest rate rise from the Federal Reserve loomed.

Deutsche Bank led a trio of Yankee borrowers in an opportunistic dash for dollar funding, as US banks were confined to the sidelines because of an earnings blackout.

Maturing deals issued by Washington Mutual and National Bank of Greece show covered bonds doing precisely what they're supposed to — redeem in full and on time.

Political wrangling on both sides of the Atlantic this week produced contrasting fortunes for two currencies in futures markets, with the Mexican peso receiving a boost and the British pound slumping to some of its worst ever levels against the US dollar.

Mizuho has hired Jason Fertig as head of healthcare investment banking for North America. Fertig joins from Nomura, where he was co-head of Americas healthcare investment banking.

US music publisher Warner Music Group on Monday was alone in the European high yield market at the same time that Verallia, the French glass packaging maker, told investors it had cancelled its pay-if-you-can bond offering.

Indian solar power company Azure Power Global has traded down on its debut on the Nasdaq stock exchange after pricing its IPO below the price guidance.

Already a pioneering issuer in the currency, the International Finance Corporation (IFC) believes greater regulatory clarity will provide a fresh boost to its onshore and offshore renminbi funding plans, Monish Mahurkar, director for treasury market operations, told GlobalRMB.

Renminbi globalisation has been successful so far, but now the low-hanging fruit has been picked, Chinese authorities will struggle to push through the next round of reforms, according to Eswar Prasad, professor at Cornell University and senior fellow at the Brookings Institution.

China Resources Pharmaceutical Group will raise as much as HK$15.6bn ($2.0bn) via a Hong Kong IPO after firming up the price range.